mRNA-4157 is a personalised vaccine targeting 34 cancer neoantigens, derived from a biopsy of a patient's tumour. In June, Moderna and MSD said they may be able to move ahead with regulatory ...
Moderna reports larger-than-expected quarterly loss Revenue falls 66% but beats expectations FDA pauses norovirus vaccine trial after adverse event report Feb 14 (Reuters) - Moderna (MRNA.O ...
Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback